Salubris Biotherapeutics Reports Updated Phase 1b/2 Data for 5T4-Targeted ADC JK06 at ESMO 2026
Salubris Biotherapeutics Presents Updated Phase 1b/2 Data for 5T4-Targeted ADC JK06 in Advanced Solid Tumors at ESMO 2026 Salubris Biotherapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing…
Mundipharma Presents Additional Phase III ReSPECT Results at IDWeek 2026
Mundipharma Reports Additional Phase III ReSPECT Results Supporting REZZAYO for Invasive Fungal Disease Prevention After Stem Cell Transplantation Mundipharma has announced additional findings from the global Phase III ReSPECT clinical…
Zai Lab Secures $250 Million in Private Placement
Zai Lab Secures $250 Million PIPE Financing to Support Global Development of Zocilurtatug Pelitecan Zai Lab Limited, an innovation-driven global biopharmaceutical company, has entered into a securities purchase agreement to…
Gilead to Acquire HCXT-2001, Expanding Its IBD Inflammation Pipeline
Gilead Sciences to Acquire PepStar’s Oral IL-23R Inhibitor Program for $1.275 Billion Gilead Sciences, Inc. has entered into a definitive agreement to acquire an oral interleukin-23 receptor (IL-23R) inhibitor program,…
Drug Farm Reports Positive Preclinical DF-003 Results for Kidney Inflammation and Fibrosis
Drug Farm Reports Positive Preclinical Findings Showing DF-003 Reduces Kidney Inflammation and Fibrosis Drug Farm has announced positive preclinical findings demonstrating that DF-003, its proprietary, first-in-class oral ALPK1 inhibitor, reduced…
Nutromics Unveils World-First Real-Time Creatinine Data at ASN Kidney Week
Nutromics Demonstrates World-First Real-Time Creatinine Monitoring in Humans Using DNA-Based Wearable Sensors Nutromics has presented what it describes as world-first real-time measurements of creatinine in humans using DNA-based sensors, marking…
Future Health and Bridge for Billions Launch Programme to Boost Health Entrepreneurship in Emerging Markets
Future Health and Bridge for Billions Launch Global Entrepreneurship Programme to Support Health Innovation in Emerging Markets Future Health – A Global Initiative by Abu Dhabi, in collaboration with Bridge…
Merck and Moderna to Present Phase 3 INTerpath-001 Results at ESMO 2026
Merck and Moderna Report Positive Phase 3 INTerpath-001 Results for Intismeran Autogene Plus KEYTRUDA in Resected Melanoma Merck, known as MSD outside the United States and Canada, and Moderna, Inc.…
Future Health and Bridge for Billions Launch Programme to Advance Health Entrepreneurship in Emerging Markets
Future Health and Bridge for Billions Launch Programme to Scale Health Innovation Across Emerging Markets Future Health, a global initiative by Abu Dhabi, is partnering with Bridge for Billions to…
Immunis Wins Grand Prize in National Academy of Medicine’s Healthy Longevity Global Competition
Immunis Wins National Academy of Medicine Grand Prize for IMM01-STEM Healthy Longevity Innovation Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy aging, has…
ViiV Healthcare Highlights Five-Year U.S. Real-World Evidence Supporting Cabenuva’s Long-Term Effectiveness and Treatment Persistence
ViiV Healthcare Reports Five-Year Real-World Evidence Supporting Long-Term Cabenuva Effectiveness in HIV Treatment ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, has…
Edwards Lifesciences Receives FDA Approval for PASCAL Precision System to Expand Treatment Options for Tricuspid Valve Disease
Edwards Lifesciences Receives FDA Approval for PASCAL Precision System for Tricuspid Valve Repair Edwards Lifesciences Corporation (NYSE: EW), a global developer of patient-focused innovations for structural heart disease, has announced…